sur The Platform Group AG (isin : DE000A2QEFA1)
The Platform Group Pursues Pharmaceutical Acquisition and Bond Issue
The Platform Group AG, based in Düsseldorf, is negotiating the acquisition of three companies operating in the pharmaceutical platform sector. The companies are located in Germany, Austria, and the Czech Republic. The Group has been involved in pharmaceuticals through its participation in ApoNow since 2021 and aims to significantly expand this sector. Letters of intent were signed in August 2025, and the company expects to finalize purchase agreements by September 2025.
Post-acquisition, TPG anticipates additional annual revenue in the low three-digit million-euro range, with an EBITDA margin of approximately 4-6%. The total purchase price is expected to be in the double-digit million-euro range. To finance these transactions, TPG may increase its existing corporate bond 2024/2028.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Platform Group AG